Surgical Site Infections (SSIs) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Surgical Site Infections (SSIs) are a devastating and common complication of hospitalization, occurring in 2% to 5% of patients undergoing surgery in the United States. SSIs lead to increased duration of hospitalization, cost, and risk of death. Each SSI leads to more than one week of additional postoperative hospital days. Most SSIs that do not involve implants are diagnosed within three weeks of surgery. SSIs are classified as either incisional or organ/ space. Incisional SSIs are further classified into superficial or deep. Organ/space SSIs include infections in tissue deep to the fascia that was opened or manipulated during surgery. For all classifications, the infection can occur within 30 days after the operation if no implant was placed or within 90 days if an implant was placed and the infection is related to the incision. SSI will occur because of a complex relationship between microbial characteristics, host characteristics, and wound characteristics.
- In the USA, ~200,000 to 300,000 Surgical Site Infections (SSIs) are being reported each year. Staphylococcus aureus is the most common cause of SSI, occurring in 20 to 25% of SSIs among hospitals.
Thelansis’s “Surgical Site Infections (SSIs) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Surgical Site Infections (SSIs) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Surgical Site Infections (SSIs) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Surgical Site Infections (SSIs) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment